Stock Taper
SCREENER COMPARE ANY 2 STOCKS
OCS
OCULIS HOLDING AG
NASDAQ
$12.21
▼ DOWN 1.77% (-0.22)

KEY STATISTICS

Market Cap$698.04 M
52w High$34.48
52w Low$10.52
Dividend Yield—
Frequency—
P/E-7.02
Volume221.87K
Shares Out.57.17M

COMPANY

LEADERSHIP

Riad Sherif
CHIEF EXECUTIVE
Riad Sherif

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 18, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
60

PRICE TARGET

Target High$50.00
Target Low$26.00
Target Median$38.00
Target Consensus$39.40

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$268.53K
NOV
5
THU

PRICE

$12.21 ▼ DOWN 1.77% (−$0.22)
$12.20$12.30$12.409:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM12.21

About Oculis Holding AG

https://oculis.com ↗

Oculis Holding AG is a Swiss clinical-stage biopharmaceutical company developing novel topical treatments for ophthalmic diseases, with candidates in various phases targeting conditions like diabetic macular edema, dry eye, and neuro-ophthalmic di...

INDUSTRY

Biotechnology

A PRODUCT OCULIS HOLDING AG IS KNOWN FOR

OCS-01
OCS-01

OCS-01 is a late-stage clinical topical eye drop aiming to become the first non-invasive treatment for Diabetic Macular Edema, potentially revolutionizing the current injection-based standard of care.

COMPETITORS

COMPETITOR
EYPT COMPARE
KOD COMPARE
OCUL COMPARE
RGNX COMPARE
TARS COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
5
LISTED HERE
5
RANKED BY POSITION SIZE
SBIO
0.36% · 70.7K
BBC
0.67% · 28.3K
ONEQ
0.00% · 25.1K
GWX
0.03% · 23.9K
GLCR
6.43% · 8.0K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
26.56%
HOLDERS
54
TOP 12 OF 54 · RANKED BY POSITION SIZE
Eqt Fund Management S.A R.L.
5.9M sh · $156.89M
Abrdn Plc
1.7M sh · $46.45M
Pivotal Bioventure Partners Investment Advisor LLC
1.7M sh · $44.68M
Wellington Management Group Llp
1.3M sh · $35.78M
Millennium Management LLC
913.0K sh · $24.28M
Adage Capital Partners Gp, L.L.C.
833.2K sh · $22.16M
Sr One Capital Management, LP
641.0K sh · $17.04M
Saturn V Capital Management LLC
516.8K sh · $13.74M
Perceptive Advisors LLC
493.8K sh · $13.13M
Eventide Asset Management, LLC
430.0K sh · $11.43M
Nan Fung Group Holdings Ltd
350.7K sh · $9.33M
Alyeska Investment Group, L.P.
331.3K sh · $8.81M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 6
OVERWEIGHT 1
OUTPERFORM 1
8 GRADES IN THE LAST 12 MONTHS
JP Morgan OVERWEIGHT HC Wainwright & Co. BUY Baird OUTPERFORM Guggenheim BUY Needham BUY Stifel BUY B of A Securities BUY Chardan Capital BUY

SECTORS PEERS

PEERPRICE
NRIX$26.21COMPARE
KOD$37.72COMPARE
URGN$43.62COMPARE
NKTR$72.52COMPARE
XNCR$26.06COMPARE
ANAB$56.28COMPARE
SANA$3.93COMPARE
PHAT$9.18COMPARE